Zymeworks (NYSE: ZYME) is one of 293 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare Zymeworks to related companies based on the strength of its profitability, dividends, institutional ownership, earnings, analyst recommendations, risk and valuation.
This table compares Zymeworks and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This table compares Zymeworks and its competitors revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Zymeworks||$11.00 million||-$33.80 million||N/A|
|Zymeworks Competitors||$264.91 million||$38.24 million||75.35|
Zymeworks’ competitors have higher revenue and earnings than Zymeworks.
Institutional and Insider Ownership
7.2% of Zymeworks shares are held by institutional investors. Comparatively, 49.0% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 17.4% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This is a summary of current ratings and target prices for Zymeworks and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Zymeworks currently has a consensus price target of $16.00, indicating a potential upside of 40.35%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 46.78%. Given Zymeworks’ competitors stronger consensus rating and higher probable upside, analysts plainly believe Zymeworks has less favorable growth aspects than its competitors.
Zymeworks competitors beat Zymeworks on 10 of the 11 factors compared.
Zymeworks Company Profile
Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company’s ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company’s platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins. The Company’s lead product candidate, ZW25, is a bispecific antibody, which is being evaluated in an adaptive Phase I clinical trial. Its ZW33 is a bi-specific antibody that delivers a cytotoxic payload to cancers cells by binding to different epitopes (bi-paratopic targeting) of the overexpressed HER2 protein. It focuses on developing a pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. It analyzes protein characteristics to develop the scope of protein engineering to tackle biological systems.
Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.